Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000146954 | SCV000194289 | benign | not specified | 2013-02-08 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000146954 | SCV000228077 | benign | not specified | 2015-08-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000146954 | SCV000513990 | benign | not specified | 2015-03-11 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001573816 | SCV000749508 | benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316944 | SCV000850113 | likely benign | Inborn genetic diseases | 2016-07-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genome- |
RCV003231339 | SCV002054891 | benign | Sotos syndrome | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV003231339 | SCV002798771 | likely benign | Sotos syndrome | 2021-07-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001573816 | SCV004158102 | likely benign | not provided | 2025-01-01 | criteria provided, single submitter | clinical testing | NSD1: BP4, BP7 |
Breakthrough Genomics, |
RCV001573816 | SCV005222560 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Laboratory of Diagnostic Genome Analysis, |
RCV001573816 | SCV001800215 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001573816 | SCV001954025 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001573816 | SCV001966301 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003952704 | SCV004775017 | benign | NSD1-related disorder | 2022-08-03 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |